Xenon Pharmaceuticals' Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Xenon Pharmaceuticals (XENE).
Over the past two years, Xenon Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
azetukalner. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Azetukalner FDA Regulatory Timeline and Events
Azetukalner is a drug developed by Xenon Pharmaceuticals for the following indication: in patients with focal onset seizures.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- azetukalner
- Announced Date:
- April 19, 2026
- Indication:
- in patients with focal onset seizures
Announcement
Xenon Pharmaceuticals Inc presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois.
AI Summary
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology Annual Meeting (April 18–22, 2026, Chicago) showing that azetukalner (AZK), a novel, potent KV7 channel opener, was effective and well tolerated in adults with focal onset seizures. The results were highlighted in a late‑breaking oral and poster session (Oral & Poster Presentation #7, LS1), where investigators reported clinically meaningful reductions in seizure frequency along with a favorable safety and tolerability profile.
The X-TOLE2 findings support AZK’s potential as a new treatment option for people with focal epilepsy. Xenon emphasized these efficacy and safety outcomes to clinicians and researchers at AAN and noted that additional data from ongoing studies will help define long‑term effects and real‑world use. The results could inform future clinical practice and continued development of AZK for focal onset seizures.
Read Announcement- Drug:
- azetukalner
- Announced Date:
- April 7, 2026
- Indication:
- in patients with focal onset seizures
Announcement
Xenon Pharmaceuticals Inc announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.
AI Summary
Xenon Pharmaceuticals announced it will present multiple abstracts at the American Academy of Neurology (AAN) Annual Meeting, April 18–22, 2026 in Chicago. The company will deliver five presentations, highlighted by a Late‑breaking Science oral and poster session revealing topline Phase 3 X‑TOLE2 results for azetukalner in focal onset seizures (FOS). This late‑breaking slot underscores the importance of the Phase 3 findings to the epilepsy field.
In addition, Xenon will present long‑term data from the X‑TOLE open‑label extension, including a poster with 48‑month azetukalner safety and durability results. Other planned abstracts cover efficacy and safety in FOS, real‑world epilepsy outcomes, and early‑stage epilepsy research, offering clinicians and researchers a broad view of azetukalner’s clinical profile and longer‑term performance.Read Announcement
- Drug:
- azetukalner
- Announced Date:
- March 9, 2026
- Indication:
- in patients with focal onset seizures
Announcement
Xenon Pharmaceuticals Inc announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.
AI Summary
Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a novel KV7 potassium channel opener for focal onset seizures (FOS). The trial met its primary endpoint in both dose groups. The 25 mg dose produced a 53.2% median reduction in monthly FOS frequency from baseline versus a 10.4% reduction for placebo (p=6×10⁻¹²).
Key secondary results showed Responder Rate 50 (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo (p=8×10⁻⁸ and p=0.003, respectively). X-TOLE2 outperformed the Phase 2b X-TOLE study, with a placebo-adjusted median percent change of −42.7% (25 mg) versus −34.6% previously. Azetukalner was generally well tolerated, with a safety profile consistent with earlier data.
Xenon plans to submit a New Drug Application for azetukalner in FOS in Q3 2026. X-TOLE2 results will be presented as a Late Breaking Science oral presentation at AAN on April 19, and the company is hosting a conference call and webcast today at 8:00 am ET.
Read Announcement- Drug:
- azetukalner
- Announced Date:
- March 7, 2026
- Indication:
- in patients with focal onset seizures
Announcement
Xenon Pharmaceuticals Inc will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.
AI Summary
Xenon Pharmaceuticals announced topline Phase 3 X-TOLE2 results for azetukalner on Monday, March 9, 2026. Azetukalner is a novel, potent KV7 potassium channel opener being developed for focal onset seizures (FOS). The study met its primary endpoint in both dose groups: the 25 mg dose produced a −53.2% median percent change (MPC) in monthly FOS frequency versus −10.4% for placebo (p=0.000000000006). X-TOLE2 outperformed the prior Phase 2b X-TOLE, with a placebo‑adjusted MPC of −42.7% for the 25 mg group versus −34.6% previously.
The trial also met a key secondary endpoint: responder rates (≥50% reduction) were 54.8% for 25 mg and 37.6% for 15 mg, compared with 20.8% for placebo (p=0.00000008 and p=0.003). Azetukalner was generally well tolerated with a safety profile consistent with earlier data. Xenon expects to submit a New Drug Application in Q3 2026, will feature the data as a Late Breaking Science presentation at AAN in April, and hosted a conference call and webcast the same day.
Read Announcement
Xenon Pharmaceuticals FDA Events - Frequently Asked Questions
As of now, Xenon Pharmaceuticals (XENE) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Xenon Pharmaceuticals (XENE) has reported FDA regulatory activity for azetukalner.
The most recent FDA-related event for Xenon Pharmaceuticals occurred on April 19, 2026, involving azetukalner. The update was categorized as "Positive Data," with the company reporting: "Xenon Pharmaceuticals Inc presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois."
Currently, Xenon Pharmaceuticals has one therapy (azetukalner) targeting the following condition: in patients with focal onset seizures.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:XENE last updated on 4/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
